Search my posts I gave numbers. They were just under 5000 reported cases of the acute hep C last year (way less than the total bc most are asymptomatic or minimally symptomatic and never see HCP ). So in one quarter to narrow a gap like they did with GILD suggests the label expansion is generating more market share in chronic hep C (as predicted if you follow this thread)